



# Rabbit (polyclonal) Anti-Ribosomal Protein S6 [pSpS<sup>244/247</sup>] Phosphospecific Antibody, Unconjugated

## PRODUCT ANALYSIS SHEET

<b>Catalog Number:</b>	44-923G (10 mini-blot size)
<b>Lot Number:</b>	See product label
<b>Volume:</b>	100 µL
<b>Form of Antibody:</b>	Rabbit polyclonal immunoglobulin in Dulbecco's phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.3 (+/- 0.1), 50% glycerol, with 1.0 mg/mL BSA (IgG, protease free) as a carrier.
<b>Preservative:</b>	0.05% sodium azide (Caution: sodium azide is a poisonous and hazardous substance. Handle with care and dispose of properly.)
<b>Purification:</b>	Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated RPS6. The final product is generated by affinity chromatography using a RPS6-derived peptide that is phosphorylated at serines 244 and 247.
<b>Immunogen:</b>	The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human RPS6 that contains serines 244 and 247. The sequence is conserved in mouse and rat.
<b>Target Summary:</b>	40S ribosomal protein S6 (also known as RPS6) is a ~31 kDa substrate of p70 S6 kinase (p70S6K) and a major component of translational machinery involved in protein synthesis, cell growth, proliferation, and metabolism. Phosphorylation of RPS6 is rapamycin and wortmannin-sensitive as its activation is mediated by mTOR and PI3K pathways. Ribosomal protein S6 undergoes phosphorylation on multiple serines in the carboxyl terminal region in the order 236→235→240→244→247, due to the positions of these amino acid residues on the α-helix. Hyperphosphorylation of ribosomal protein S6 stimulates protein synthesis that mediates progression through the cell cycle.
<b>Reactivity:</b>	Human RPS6. Mouse and rat RPS6 (100% homologous) have not been tested, but are expected to react. This antibody does not cross react with RPS6 phosphorylated on serines 235 and 236.
<b>Applications:</b>	The antibody has been used for Western blotting applications.
<b>Suggested Working Dilutions:</b>	For Western blotting applications, we recommend using the antibody at a 1:1000 dilution. The optimal antibody concentration should be determined empirically for each specific application.
<b>Storage:</b>	Store at -20°C. We recommend a brief centrifugation before opening to settle vial contents. Then, apportion into working aliquots and store at -20°C. For shipment or short-term storage (up to one week), 2-8°C is sufficient.
<b>Expiration Date:</b>	Expires one year from date of receipt when stored as instructed.
<b>Positive Control Used:</b>	HeLa +/- TNF-α or anisomycin.

**This product is for research use only. Not for use in diagnostic procedures.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)  
This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44923G

(Rev 11/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

## Related Products:

## Antibodies:

Ribosomal Protein S6 [pSpS<sup>235/236</sup>], Cat. # 44-922G  
p70S6K [pT<sup>229</sup>], Cat. # 44-918  
Anti-Akt/PKB pan, Cat. # 44-609G  
Akt/PKB [pT<sup>308</sup>], Cat. # 44-602G  
Akt/PKB [pS<sup>473</sup>], Cat. # 44-621G  
PKR [pT<sup>451</sup>], Cat. # 44-668G  
eIF2 $\alpha$  [pS<sup>52</sup>], Cat. # 44-728G  
eIF4G [pS<sup>1108</sup>], Cat. # 44-526  
Src [pY<sup>418</sup>], Cat. # 44-660G  
ERK1&2 [pTpY<sup>185/187</sup>], Cat. # 44-680G  
PTEN [pS<sup>370</sup>], Cat. # 44-1060G  
PTEN [pSpTpS<sup>380/382/385</sup>], Cat. # 44-1066G

## References:

Pende, M., et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol. Cell. Biol.* 24(8):3112-3124.

Mourani, P.M., et al. (2004) Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. *Circulation* 109(10):1299-1306.

Lekmine, F., et al. (2004) Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. *Exp. Cell. Res.* 295(1):173-182.


Tuhackova, Z., et al. (2004) IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells. *Int. J. Mol. Med.* 13(4):601-605.

Ly, C., et al. (2003) Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. *Cancer Res.* 63(18):5716-5722.

Shah, O.J., et al. (2003) Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2. *J. Biol. Chem.* 278(18):16433-16442.

Stewart, M.J. and G. Thomas (1994) Mitogenesis and protein synthesis: a role for ribosomal protein S6 phosphorylation? *Bioessays.* 16(11):809-815. Review.

Ferrari, S., et al. (1991) Mitogen-activated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. *J. Biol. Chem.* 266(33):22770-22775.



### Peptide Competition

Lysates prepared from HeLa cells left untreated (1) or treated with TNF- $\alpha$  (2-5) were resolved by SDS-PAGE on a 14% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer for one hour at room temperature, and incubated with ribosomal protein S6 [pSpS<sup>244/247</sup>] antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 2), the non-phosphopeptide corresponding to the immunogen (3), a generic phosphoserine-containing peptide (4), or, the phosphopeptide immunogen (5). After washing, membranes were incubated with goat F(ab')<sub>2</sub> anti-rabbit IgG HRP conjugate (Cat. # ALI4404) and bands were detected using the Pierce SuperSignal<sup>TM</sup> method.

The data show that only the peptide corresponding to ribosomal protein S6 [pSpS<sup>244/247</sup>] blocks the signal, verifying the specificity of the antibody.

**This product is for research use only. Not for use in diagnostic procedures.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44923G

(Rev 11/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

## Western Blotting Procedure

1. Lyse approximately  $10^7$  cells in 0.5 mL of ice cold Cell Lysis Buffer (formulation provided below). This buffer, a modified RIPA buffer, is suitable for recovery of most proteins, including membrane receptors, cytoskeletal-associated proteins, and soluble proteins. This cell lysis buffer formulation is available as a separate product which requires supplementation with protease inhibitors immediately prior to use (Cat. # FNN0011). Other cell lysis buffer formulations, such as Laemmli sample buffer and Triton-X 100 buffer, are also compatible with this procedure. Additional optimization of the cell stimulation protocol and cell lysis procedure may be required for each specific application.
2. Remove the cellular debris by centrifuging the lysates at 14,000 x g for 10 minutes. Alternatively, lysates may be ultracentrifuged at 100,000 x g for 30 minutes for greater clarification.
3. Carefully decant the clarified cell lysates into clean tubes and determine the protein concentration using a suitable method, such as the Bradford assay. Polypropylene tubes are recommended for storing cell lysates.
4. React an aliquot of the lysate with an equal volume of 2x Laemmli Sample Buffer (125 mM Tris, pH 6.8, 10% glycerol, 10% SDS, 0.006% bromophenol blue, and 130 mM dithiothreitol [DTT]) and boil the mixture for 90 seconds at 100°C.
5. Load 10-30 µg of the cell lysate into the wells of an appropriate single percentage or gradient minigel and resolve the proteins by SDS-PAGE.
6. In preparation for the Western transfer, cut a piece of PVDF membrane slightly larger than the gel. Soak the membrane in methanol for 1 minute, then rinse with ddH<sub>2</sub>O for 5 minutes. Alternatively, nitrocellulose may be used.
7. Soak the PVDF membrane, 2 pieces of Whatman paper, and Western apparatus sponges in transfer buffer (formulation provided below) for 2 minutes.
8. Assemble the gel and membrane into the sandwich apparatus.
9. Transfer the proteins at 140 mA for 60-90 minutes at room temperature.
10. Following the transfer, rinse the membrane with Tris buffered saline for 2 minutes.
11. Block the membrane with blocking buffer (formulation provided below) for one hour at room temperature or overnight at 4°C.
12. Incubate the blocked blot with primary antibody at a 1:1000 dilution in Tris buffered saline supplemented with 3% BSA and 0.1% Tween 20 for one hour at room temperature or overnight at 4°C.
13. Wash the blot with several changes of Tris buffered saline supplemented with 0.1% Tween 20.
14. Detect the antibody band using an appropriate secondary antibody, such as goat F(ab')<sub>2</sub> anti-rabbit IgG alkaline phosphatase conjugate (Cat. # ALI4405) or goat F(ab')<sub>2</sub> anti-rabbit IgG horseradish peroxidase conjugate (Cat. # ALI4404) in conjunction with your chemiluminescence reagents and instrumentation.

### Cell Lysis Buffer

#### Formulation:

10 mM Tris, pH 7.4  
100 mM NaCl  
1 mM EDTA  
1 mM EGTA  
1 mM NaF  
20 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>  
2 mM Na<sub>3</sub>VO<sub>4</sub>  
0.1% SDS  
0.5% sodium deoxycholate  
1% Triton-X 100  
10% glycerol  
1 mM PMSF (made from a  
0.3 M stock in DMSO)  
or 1 mM AEBSF (water  
soluble version of PMSF)  
60 µg/mL aprotinin  
10 µg/mL leupeptin  
1 µg/mL pepstatin  
(alternatively, protease inhibitor cocktail  
such as Sigma Cat. # P2714 may be used)

### Transfer Buffer

#### Formulation:

2.4 gm Tris base  
14.2 gm glycine  
200 mL methanol  
Q.S. to 1 liter, then add  
1 mL 10% SDS.  
Cool to 4°C prior to use.

### Tris Buffered Saline

#### Formulation:

20 mM Tris-HCl, pH 7.4  
0.9% NaCl

### Blocking Buffer

#### Formulation:

100 mL Tris buffered saline  
5 gm BSA  
0.1 mL Tween 20

**This product is for research use only. Not for use in diagnostic procedures.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44923G

(Rev 11/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.